Prostate Cancer Coverage from Every Angle

Concurrent Enzalutamide, Salvage Radiotherapy, and ADT in High-Risk Prostate Cancer

By: Kayci Reyer
Posted: Monday, May 4, 2020

According to research published in European Urology Oncology, concurrent enzalutamide, salvage radiotherapy, and androgen-deprivation therapy (ADT) is safe for use in patients with high-risk recurrent prostate cancer. The 3-year trial focused on men with prostate-specific antigen (PSA) recurrence within 4 years of undergoing radical prostatectomy and an elevated Gleason score.

“Salvage [radiotherapy] with enzalutamide and ADT following [radical prostatectomy] for men with PSA recurrent high-risk [prostate cancer]…demonstrates encouraging efficacy, warranting prospective controlled phase II trials of ADT with or without potent androgen receptor inhibition in this curative-intent setting,” concluded Rhonda L. Bitting, MD, of Wake Forest University, Winston-Salem, and colleagues.

The study focused on 37 men with prostate cancer who had a Gleason score between 7 and 10 and who had PSA recurrence of between 0.2 and 4.0 ng/mL within 4 years of undergoing radical prostatectomy. The 2-year progression-free survival was 65% (95% confidence interval [CI] = 47%–78%), superior to the 51% achieved in a similar trial where docetaxel was used in place of enzalutamide (95% CI = 33%–67%). Progression-free survival at 3 years was 53%.

No unexpected toxicities were reported. A total of 29% of patients (n = 11) experienced grade 3 toxicities, but no toxicities of a higher grade were observed. According to quality-of-life data, a slight increase in bowel, bladder, and hormonal symptoms occurred around 3 months but resolved by 24 months for the majority of affected patients.

“Addition of 6 months of oral daily enzalutamide to standard salvage radiation and hormone therapy…may improve prostate cancer remission rates at 2 and 3 years,” the study authors concluded.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.